Natco Pharma has received Establishment Inspection Report (EIR) from U.S. Food and Drug Administration (USFDA) for Active Pharmaceutical Ingredient (API) division located in Manali, Chennai. The said facility has received Voluntary Action Indicated (VAI) classification.
The inspection had conducted from November 17, 2025 to November 21, 2025. The Company received seven observations in the Form-483.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
